Tilray Brands Inc vs 22nd Century Group Inc — how do they compare? Tilray Brands Inc trades at $3.54 (market cap $530.54M), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Tilray Brands Inc is far larger — about 853.4× 22nd Century Group Inc's market cap, and 22nd Century Group Inc is more actively traded (45,625 versus 9,099,075). Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and 22nd Century Group Inc for 32 Days on average.
| TLRY | XXII | |
|---|---|---|
Market Cap | $530.54M | $621.67K |
Volume | 9,099,075 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $21.00 | $483.00 |
52-Week Low | $3.57 | $0.80 |
Typical Hold Time | 31 Days | 32 Days |
Enterprise Value | $684.46M | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →